Premium
Biodistribution and urinary excretion of 4‐IODO‐L‐ meta ‐tyrosine
Author(s) -
Shikano N.,
Kawai K.,
Flores Ii L. G.,
Nishii R.,
Kubodera A.
Publication year - 2001
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.25804401123
Subject(s) - chemistry , excretion , urine , probenecid , biodistribution , kidney , urinary system , tyrosine , medicine , endocrinology , biochemistry , in vitro
We examined the biodistribution and urinary excretion of 125 I‐4‐iodo‐L‐ meta ‐tyrosine (4‐ 125 I‐L‐mTyr) in mice, in order to compare the results with that of 3‐[ 125 I]iodo‐alpha‐methyl‐L‐tyrosine ( 125 I‐L‐AMT). Three hours after administration, more than 70% of the excretion of 4‐ 125 I‐L‐mTyr was in the urine, and less than 5% was found in the feces. The kidney homogenate and urine analysis on its metabolites revealed that most of the accumulated radioactivity belonged to intact 4‐ 125 I‐L‐mTyr (>95%). These results indicated its high metabolic stability, which was comparable to 125 I‐L‐AMT stability. However, the blood clearance of 4‐ 125 I‐L‐mTyr was faster than that of 125 I‐L‐AMT. 4‐ 125 I‐L‐mTyr accumulation in mouse kidney cortex was approximately 80% lower than that of 125 I‐L‐AMT. Probenecid reduced the 4‐ 125 I‐L‐mTyr accumulation in the kidney and urinary excretion, similar to 125 I‐L‐AMT.